8.1 Discontinuation from Study Treatment ............................................................ 63 63 63 63 64 64 64 65 67 67 68 69 69 69 69 78 80 80 81 81 82 83 8484 84 85 87 88 88 89 90 91 91 91 91 92 92 92 93 93 93Clinical Protocol BMS-986226CA021002 anti-ICOS Revised Protocol No.: 04Date: 31-May-2019 7 Approved 5.0 v Approved 1.0 v 8.1.1 Criteria to Resume Treatment .................................................................. 8.1.2 Treatment Beyond Disease Progression ..................................................